Home » Stocks » ALZN » Company

Alzamend Neuro, Inc. (ALZN)

Stock Price: $4.42 USD -0.49 (-9.98%)
Updated Jul 27, 2021 4:00 PM EDT - Market closed
Alzamend Neuro, Inc.
Country United States
Founded 2016
IPO Date Jun 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 1
CEO Stephan Jackman

Contact Details

Address:3802 Spectrum Blvd,
Tampa, Florida 33612
United States
Phone 844-722-6333

Stock Information

Ticker Symbol ALZN
Exchange NASDAQ
Fiscal Year May - April
Reporting Currency US Dollars
IPO Price $5.00
CIK Code 1677077
Employer ID 81-1822909

Company Description

Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders.

With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Our primary target is Alzheimer’s disease.

Existing Alzheimer’s treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects roughly 6.2 million Americans and that number is expected to grow to 13 million individuals by 2050.

Our lead product candidate that we have licensed and will first move to clinical development in humans is an ionic cocrystal of lithium for the treatment of Alzheimer’s and other neurodegenerative diseases and psychiatric disorders.

We submitted a Pre-Investigational New Drug (“PIND”) briefing package to the FDA in July 2019 and have begun the process of finalizing the Investigational New Drug (“IND”) application.

We currently expect to submit by June 30, 2021 the IND for FDA approval to begin a Phase I clinical trial with human subjects. We have an additional preclinical candidate for Alzheimer’s indication, AL002, which has transitioned from early-stage development to an extensive program of preclinical study and evaluation, with an anticipated completion date of May 31, 2021.

Key Executives

Stephan JackmanChief Executive Officer and Director
Kenneth S. Cragun CPAChief Financial Officer and Treasurer
Henry C.W. Nisser Esq.Executive Vice President, General Counsel and Director
Milton Charles Ault IIIFounder and Executive Chairman
Lien T. EscalonaChief Financial Officer
David J. KatzoffChief Operating Officer